Rhythm Pharmaceuticals Inc.
(NASDAQ:RYTM) stock is trading higher on Monday after the company reported preliminary results from an ongoing Phase 2 study evaluating setmelanotide in patients with Prader-Willi syndrome (PWS).
The six-month data shared on Saturday showed improvements in body mass index, body composition, hyperphagia, and behavioral measures.
The company presented the findings at the Endocrine Society's Annual Meeting, ENDO 2026.
Read Also: Rhythm Pharma Wins FDA Approval For First-Ever Rare Weight Disorder Therapy The trial enrolled 18 patients between the ages of 6 and 23 who met obesity-related eligibility criteria.
